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Abstract: The spondyloarthropathies are a group of arthritides which specifically target the 
spine and pelvis with ankylosing spondylitis (AS) being the most prevalent and debilitating 
of these conditions. Unique to AS is the progression to excessive uncontrolled bone formation 
following an initial inflammatory phase that can result in joint fusion and significant disability. 
Spondyloarthritis is estimated to affect 1%–2% of the population, twice as many as rheumatoid 
arthritis and thus constitutes a significant health problem. Currently AS pathogenesis is very 
poorly understood but recent large-scale genetics and gene expression profiling studies have 
identified some of the underlying mechanisms and pathways contributing to the disease. 
Genome-wide association studies have identified a number of candidate genes associated with 
AS sharing the same pathways which are now being targeted for therapeutic intervention. 
However, although such approaches can identify genes contributing to the disease process and 
are very informative as to disease aetiopathogenesis, they cannot profile the actual changes in 
gene/cell activity at any point in the disease process or possibly more importantly at specific 
sites. Such information is generated using expression profiling. A number of expression profiling 
studies have been undertaken in AS, looking at both circulating cells and tissues from affected 
joints. Although some common genes/pathways have been identified, overall the results to date 
have been somewhat disappointing due to differences in experimental design and tissue source 
as well as the low power of the studies. More recent better powered studies have shown some 
potential in developing gene expression profiling as a diagnostic tool in AS. True future success 
will rely on larger genetic and genomic studies and the combination of these datasets in eQTL 
studies requiring significant collaborative efforts. Such larger-scale approaches will also generate 
sufficient power to target specific disease stages and sites.
Keywords: ankylosing spondylitis, genomewide association studies, gene expression, 
microarrays, spondylarthritis, inflammatory arthritis
Introduction
The spondyloarthropathies are estimated to affect 1%–2% of the population almost 
 two-fold higher prevalence than rheumatoid arthritis (RA).1 AS is the prototypic and 
most prevalent spondyloarthropathy and affects between 0.1%–1.4% of the global 
 population. The condition primarily affects the spine and sacroiliac joints of the pelvis, 
causing pain and stiffness and eventual fusion. Asymmetric peripheral joint arthritis 
(∼20%) and episodic acute anterior uveitis (∼40%) are also common and approximately 
10% of AS cases also have either inflammatory bowel disease (IBD) or psoriasis, while 
approximately 70% have sub-clinical gut inflammation. The disease onset is typically 
in the second decade of life and thus the disease has a higher impact relative to later 
onset diseases, such as rheumatoid arthritis, due to its longer disease duration.
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Clinical features
The clinical features of AS can be divided into axial and 
peripheral components. Axial features include spondylitis, 
sacroiliitis and skeletal complications. Peripheral features 
include enthesitis, peripheral arthritis, inflammatory bowel 
disease (IBD) and anterior uveitis.
Axial features
Axial disease most commonly presents as inflammatory lower 
back pain and morning stiffness.2 Morning stiffness lasts 
from one to several hours and is improved by exercise but 
not relieved by rest (as in the case of mechanical back pain).3 
Lower back pain results from inflammation of the SI joints 
and the vertebrae. Sacroiliitis, inflammation of the SI joint, is 
the most common feature of AS. Sacroiliitis can be detected 
by conventional x-ray of the pelvis which shows joint space 
narrowing and eventual sclerosis of the joint (Figure 1).
A distinguishing feature of AS is the site of the initial 
inflammation. This occurs at the entheses, the sites where 
tendons or ligaments join bone resulting in enthesitis one of 
the earliest features of AS (Figure 2). The stooped posture 
characteristic of AS patients is caused by inflammation of the 
spine and formation of syndesmophytes, bone growths origi-
nating from the initial sites of inflammation. In the spine of 
AS patients syndesmophytes form in the intervertebral joints 
and lead to fusion of the vertebrae which sometimes results 
in a classical ‘bamboo spine’ appearance. Fusion of bone 
across intervertebral joints ultimately causes flattening of the 
lumbar spine and limits neck motion and chest expansion. 
Paradoxically for a disease that induces new bone formation 
AS patients frequently exhibit reduced bone mineral density 
leading to osteoporosis driven by the high levels of inflam-
matory molecules associated with the disease.
Peripheral features
Arthritis of peripheral joints including hips, shoulders, 
knees, wrists, ankles and elbows is common in AS.4 
Radiographically the peripheral arthritis in AS is similar to 
that observed in rheumatoid arthritis (RA). However, in AS 
additional ankylosis of wrists, hips, tarsal joints and small 
joints in the fingers and toes is common. Peripheral joint 
arthritis is usually asymmetric.5
Extra-articular features
iBD
A close relationship exists between gut inflammation and 
AS. Approximately two-thirds of AS cases display signs 
of gut inflammation unrelated to clinical gastrointestinal 
symptoms, and AS cases and their first-degree relatives have 
increased gut permeability.6 As will be discussed in more 
detail later many genetic associations are shared between 
AS and both Crohn’s disease and ulcerative colitis, including 
IL-23R, STAT3, CARD9, IL12B, PTGER4, and KIF21B.7 
These findings suggest common pathogenic processes shared 
between IBD and AS. Reactive arthritis, an AS- related 
spondyloarthritis, can result from acute gastrointestinal 
infections, and these findings suggest that the gut is a major 
source of antigenic drive in AS.
Normal lateral
lumbar spine
Normal lateral
cervical spine
Fused lateral
lumbar spine
Fused lateral
cervical spine
Normal SI joint Fused SI joint
Figure 1 Axial inflammation in AS. In normal lumbar and cervical spine x-rays clear 
delineation of the intervertebral spaces is evident. However in severely affected 
fused spinal x-rays extensive bridging across the vertebrae is evident (arrows). In the 
sacroiliac (SI) joints in normal subjects the joint space is clearly visible (arrows) but 
in severely affected cases, fusion is evident with blurring of the joint space (arrows). 
images courtesy of Linda Bradbury at the University of Queensland Diamantina 
institute.
Figure 2 enthesitis of the Achilles tendon. 
Note: Arrows indicate severe inflammation of the Achilles tendon (enthesitis). 
image courtesy of Linda Bradbury at the University of Queensland Diamantina institute.
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However the association between gut and joint disease is 
not fully understood. Activated T cells expressing members 
of the β7 family of integrins, which are involved in homing 
of intestinal lymphocytes, are enriched in the synovium of 
Spondyloarthropathy patients suggesting an intestinal origin 
to these cells.8
Anterior uveitis
Acute anterior uveitis (AAU) affects approximately 40% of 
patients with AS and approximately half of all AS patients 
with AU are B27+.9 AAU is normally unilateral and char-
acterised by red, sore eyes, increased tear production and 
photophobia. AAU does not precede axial or peripheral 
inflammation but is often the first clinical sign presented to 
doctors by patients who may have lived with lower back pain 
for several years.
Cardio vascular disease
Recently it has been reported that AS patients are at 
increased risk for many cardiovascular disorders compared 
with the general population.10 The cardiovascular diseases 
include aortic valvular heart disease, non-aortic valvular 
heart disease, ischemic heart disease and congestive heart 
failure. Risk of developing these cardiovascular diseases is 
greatest in younger AS patients.10 The reasons for increased 
risk of cardiovascular events in AS patients are unclear. 
While it is difficult to determine the contribution of disease 
to mortality rates a recent study compared mortality among 
almost 700 AS patients and age, sex and locality-matched 
controls and found increased mortality in the AS group with 
circulatory disease the most frequent cause of death among 
the AS cases.11
Aetiology and pathology
There is a strong genetic component in the risk of developing 
AS. Studies in twins have estimated heritability of AS 
at .90%.12 HLA-B27 is established as the major genetic 
risk factor and the association between HLA-B27 and AS is 
among the strongest genetic association with any common 
disease. The genetic aetiology of AS will be discussed in 
greater detail below. Males are more frequently affected than 
females at a ratio of 2.5:1. The reasons for this imbalance 
are unclear.
The initial trigger for AS is currently unknown. With 
few exceptions, AS has a worldwide distribution, indicating 
that whatever the trigger it must be ubiquitous. Furthermore, 
epidemics of AS have not been reported. Studies in the B27 
transgenic rat model of AS support the idea of a ubiquitous 
environmental trigger; B27 transgenic rats exposed to normal 
commensal bacteria develop disease while rats maintained in 
germ-free conditions do not.13 It has been suggested that this 
ubiquitous environmental factor may be a  common microbial 
pathogen.14–16 A genetic defect reducing the immune system’s 
ability to clear the pathogen could result in a low-level 
sub-clinical infection which may result in the autoimmune 
response seen through the pathogen presenting self- antigens 
or the pathogen’s antigens mimicking  self-antigens. 
Immune cells express various molecules capable of sens-
ing a wide variety of microbial peptides. These include 
toll-like receptors (TLR), Dectin-1, PAMPs and DAMPs. 
Defects in recognition of microbial products by immune 
cells may contribute to an inflammatory cascade, driven by 
inflammatory cytokines such as IL-23, IL-1 and IL-6. The 
relative contributions of innate and adaptive immunity to 
the pathogenesis of AS is still unclear. Understanding the 
precise role of different immune cell types during different 
stages of disease and at different sites of disease is important 
for understanding how to develop novel targeted therapies. 
Recent studies in our lab have demonstrated that over 25% 
of γδ T cells in the peripheral blood of AS patients with 
active disease express IL-23R, secrete large amounts of 
IL-17 and display a strong Th17 bias.17 This data suggests 
an important role for γδ T cells in pathogenesis of AS. Given 
that γδ T cells bridge the innate-adaptive systems express-
ing myriad activation receptors such as Dectin-1, Toll-like 
receptors and NKG2D as well as IL-23R and IL-1, they 
are attractive candidate cells for further investigation in the 
pathogenesis of AS.
AS has two phases, an initial inflammatory phase fol-
lowed by an osteoproliferative/ankylosing phase where the 
joint fusion is initiated and progresses. The inflammatory 
phase has similarities with other inflammatory arthrites 
such as RA with high levels of pro-inflammatory cytokine 
production and joint damage through osteoclast activity. 
However, the extent of joint destruction though the cytokine/
osteoclast axis is significantly less than in RA with the 
dominant joint impact stemming from ankylosis occurring 
as a result of osteoproliferation. The most common site of 
this excessive bone formation in AS is in the cervical and 
lumbar vertebrae resulting in squaring of the vertebrae and 
eventually formation of syndesmophytes from the vertebral 
corners which can eventually bridge leading to ankylosis. 
Whether the initial inflammation directly links to the sub-
sequent osteoproliferative stages is subject to significant 
debate. There is little evidence for a direct link between the 
two with some evidence that they are temporally distinct.18,19 
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This is supported by studies of the MRI evidence of inflam-
mation and the subsequent development of syndesmophytes. 
These show that whilst there is an increased rate of syndesmo-
phytes formation at vertebral corners with preceding MRI evi-
dence of inflammation, most syndesmophytes arise at corners 
with no prior evidence of inflammation, and most corners 
with evidence of inflammation do not go on to develop 
syndesmophytes.20,21 These studies are consistent with models 
in which inflammation precedes bone formation but in which the 
link between inflammation and bone formation is not as 
direct as, for example, the link between inflammation and 
erosion in RA.22,23 There are therefore two key triggers in AS 
that are currently unknown; the signal for disease initiation, 
and the switch from inflammation to the damaging osteo-
proliferation phase. Elucidation of these triggers would be a 
major advance and identify new therapeutic approaches.
Treatment
The goal of treatment within AS is two-fold: to reduce 
pain and disability and to prevent progression of disease. 
 Current therapies have provided symptom relief and reduced 
disability but have shown no efficacy in preventing or even 
slowing progression of disease. A key issue is the difficulty 
in diagnosing AS. Currently, firm diagnosis of AS requires 
confirmation of joint deterioration by X-ray (Modified New 
York Criteria),24 which only occurs in quite advanced disease, 
leading to an average delay between onset of symptoms and 
diagnosis of 8–11 years. Early diagnosis of AS would allow 
treatment to be commenced before significant joint dam-
age has occurred possibly increasing the potential to slow 
disease progress. Trials investigating the effectiveness of this 
approach are currently underway.
Unlike patients with rheumatoid arthritis, AS patients 
respond well to physical therapy and long periods of 
immobility increase pain and immobility. Supervised group 
physiotherapy shows best symptom relief compared with 
group exercise or home exercise programs.25
Conventional anti-rheumatic drugs such as methotrexate 
and sulfazalazine are ineffective in treatment axial disease 
in AS. However, they show some efficacy in management of 
peripheral and extra-articular features including psoriasis and 
uveitis.26,27 Non-steroidal anti-inflammatory drugs (NSAIDS) 
are the first line of medication for treatment of pain and 
stiffness in AS. NSAIDS such as naproxen provide some 
symptom relief and have been shown to significantly reduce 
inflammatory markers like c-reactive protein in blood of AS 
patients.28 However, long term NSAID treatment has the 
potential for gastrointestinal and cardiovascular toxicity.
The most effective symptom relief is obtained through 
use of the TNF-antagonist family of medications. Anti-TNF 
therapy provides substantial symptom relief and has effects 
on many of the axial, peripheral and extra-articular features 
of AS.29–32 However, while anti-TNF therapy reduces inflam-
mation and prevents further joint destruction33 it neither pre-
vents nor slows bone formation.34–36 Side effects of long-term 
anti-TNF therapy include increased susceptibility to tubercu-
losis infection due to systemic immune suppression.37
Since no treatment to date has been shown to have an 
effect on preventing or slowing the natural course of disease 
there is a very great need for research to determine what 
triggers disease and to better understand the inflammatory 
pathways involved in AS, thereby providing novel therapeu-
tics options. Recent advance in the genetics and genomics 
of AS have highlighted several important pathways involved 
in AS. We review here some of those advances and highlight 
some of the functional consequences of the genetic associa-
tions with AS. Further genetic and gene expression studies 
can generate diagnostic algorithms to aid in early disease 
detection and improved treatment regimes.
AS genetics
As stated above, AS is a largely genetically controlled 
 disease. Familial aggregation indicating the presence of 
shared susceptibility factors has been long observed,38 and 
studies of disease concordance in twins and families have 
shown that disease susceptibility is largely controlled by 
genetic factors.12,39 Twin studies have shown concordance to 
be 75% (6/8) in monozygotic twins, 27% (4/15) for dizygotic 
twins sharing HLA-B27 and 12.5% (4/32) for dizygotic twins 
overall.12 AS is highly heritable, with additive genetic factors 
estimated to account for .90% of susceptibility.12 Age of 
onset (40%) and disease severity, as measured by the widely 
accepted BASDAI (51%) and BASFI (76%) questionnaires, 
are also highly heritable.40,41 Below we discuss some of the 
more established loci contributing to this heritability.
MHC
The most significant AS-associated genetic locus is the major 
histocompatibility complex (MHC) on chromosome 6p. This 
genetic association is predominantly due to the association of 
AS with HLA-B27, however there is evidence for association 
with other MHC alleles.
HLA-B27
The association of HLA-B27 has been recognised since 
the early 1970s,42–44 and is among the strongest genetic 
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associations with a common disease. HLA-B27 is  carried 
by approximately 8% of white Europeans, compared with 
3% to 5% of Han Chinese,45 and is rare in African populations 
(which accounts for the low incidence of AS in Africans).46 
Around 80% to 95% of AS patients are HLA-B27 positive, yet 
only 1% to 5% of HLA-B27 carriers develop AS,47–50 therefore 
screening has not been useful as a sole diagnostic.
There are over 40 different allelic variants of HLA-B27 
reported, all of which are ancestrally related to the B*2705 
variant.51 95% of white British HLA-B27 carriers have this 
subtype.51 while Chinese populations mainly have a mixture 
of B*2704 and B*2705.45 Of the many HLA-B27 subtypes 
identified, the majority are rare and their influence on AS 
has not been investigated.
Although the association between HLA-B27 and AS 
has been known for many years, the mechanism of disease 
association is still unclear. The “arthritogenic peptide” theory 
focuses on the canonical functions of HLA-B27 in antigen 
presentation to cytotoxic T-lymphocytes.52–56 The hypothesis 
suggests that after pathogenic insult, HLA-B27 presents 
a microbial epitope and elicits a CTL response against it. 
However, some of the CTLs may cross-react with any self anti-
gens showing molecular mimicry with the microbial epitope. 
The reaction of CD8+ CTLs with self antigen would result in 
autoimmune tissue injury and inflammation. Association of 
ERAP1, the gene encoding the protein endoplasmic reticulum 
aminopeptidase 1 (ERAP1), with AS is only seen in HLA-
B27 positive cases. This suggests that in HLA-B27- positive 
disease aberrant peptide trimming or presentation by ERAP1 
and HLA-B27 are involved in AS pathogenesis,57 and this will 
be further discussed later.
Non-canonical theories involve properties of HLA-B27 
itself. These include the “misfolded protein”  hypothesis, in 
which the slow folding of the HLA-B27 heavy chain causes 
misfolded proteins that accumulate in the  endoplasmic 
reticulum in the form of covalent homodimers and multim-
ers.58,59 This accumulation of misfolded proteins causes ER 
stress, which results in inflammation through the activation 
of the unfolded protein response (UPR) and the ER-overload 
response (EOR).60
An extension of the misfolding hypothesis is the HLA-
B27 surface homodimer hypothesis.61 Covalently linked 
HLA-B27 homodimers have been found to be expressed 
on the cell surface, however they have not been secreted 
to the cell surface from the ER.62–64 Signalling through 
these non-canonical forms of HLA-B27 may play an 
immunomodulatory role and upset the normal development 
of HLA class-I responses, with unusual signalling causing 
excessive pro-inflammatory cytokine release. Additionally, 
HLA-B27 homodimer expressing APCs have been shown 
to stimulate the survival, proliferation and IL-17 produc-
tion of Th17 cells that express the NK-receptor KIR3DL2 
in AS patients.65 This observation provides a link between 
HLA-B27 and the IL-23 signalling pathway, which will be 
discussed later.
Other MHC genes
As well as the overwhelming association with HLA-B27, AS 
also shows association with other genes in the MHC. The 
MHC class I gene HLA-B60 has been shown to be associated 
with AS in a UK population.66 HLA-B60 shows association 
with both B27-positive and negative AS, and this association 
has been replicated in a Chinese population.67
The MHC class II gene HLA-DRB1 has been found to 
be associated with AS in B27 matched case control studies68 
and twin studies.12 A study of non-B27 MHC associations of 
AS using B27-matched haplotypes in cases and controls has 
shown that HLA-DRB1 is associated with AS irrespective 
of whether the haplotype contained HLA-B27.69 This may 
contribute to disease by causing aberrant presentation to or 
selection of CD4+ lymphocytes.
Non-MHC genes
Very little progress was made in the identification of genes 
associated with AS in the years following the discovery of 
the HLA-B27 association. A number of linkage studies were 
performed, identifying association with the interleukin-1 
(IL-1) gene complex and CYP2D6. There have been  several 
reports of IL-1 complex association with AS,70–72 including 
reported association in a Chinese population.73 The IL-1 gene 
complex includes genes encoding the pro-inflammatory cytok-
ines IL-1α, IL-1β and their naturally occurring inhibitor IL-1 
receptor agonist (IL-1RA). IL-1 is involved in the induction of 
chemokine and adhesion  molecule expression in various cells 
types, and variation within the IL-1 cluster may contribute to 
AS pathogenesis through altered inflammation.
Association with AS has also been found for CYP2D6, 
the gene that encodes cytochrome P450 debrisoquine 
4- hydroxylase.48,74 It is possible that CYP2D6 is involved in 
the metabolism of a ubiquitous environmental factor involved 
in AS, and that reduced enzymatic activity could lead to 
increased disease susceptibility, however this association has 
not been seen in more recent studies.
In recent years there have been a number of studies in 
which non-MHC genes have been reported as being associated 
with AS, most of which have been undertaken in populations 
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of white-European heritage with confirmed disease according 
to the Modified New York Criteria. The first study to convinc-
ingly identify non-MHC associations with AS was a study of 
14,500 non-synonymous SNPs performed by the Wellcome 
Trust Case Control Consortium (WTCCC) and the Australo-
Anglo-American Spondyloarthritis Consortium (TASC), in 
which associations with ERAP1 and IL23R were identified75 
in a cohort of 1000 AS patients and 1500 healthy controls. 
The first genome-wide association study (GWAS) in AS was 
performed by TASC, using Illumina HumHap370 genotyping 
chips in a cohort of 2500 AS patients and 5000 healthy controls, 
with replication in a cohort of 900 cases and 1500 controls. 
This study identified the genes IL1R2 and ANTXR2 as being 
associated with AS, as well as gene deserts at chromosomes 
2p15 and 21q22.76 This was followed by a second GWAS 
performed by TASC and the Wellcome Trust Case Control 
Consortium 2 (WTCCC2),using Illumina 660W-Quad and 
Human 1.2M-Duo chips in a cohort of 3000 AS patients 
and 4800 controls, with replication in a cohort of 2100 cases 
and 4500 controls. Association was found with genes includ-
ing RUNX3, LTBR-TNFRSF1 A and IL12B.57 In addition to 
this there have been a number of smaller studies performed 
in a variety of populations. Table 1 summarizes the genes 
confirmed to be associated with AS with genome-wide 
significance from the GWAS performed to date.
Class i presentation associated  
genes – ERAP1 and RUNX3
ERAP1 was first reported to be associated with AS in the 
WTCCC/TASC nsSNP study,75 and this association has been 
confirmed both the TASC76 and WTCCC2/TASC GWAS,57 
as well as in a number of different ethnicities including 
 Chinese,77,78 Portuguese,79 Korean80 and Hungarian.81 ERAP1 
has also been shown to be associated with psoriasis in both 
white European82 and Chinese83 populations.
There are two known roles of ERAP1, both of which may 
explain the association with AS. ERAP1 is involved in the 
trimming of peptides within the endoplasmic reticulum to 
optimal length for MHC class I presentation.84,85 The strong 
association with HLA-B27 indicates that AS is primarily an 
MHC class I mediated disease, but the way B27 increases 
disease susceptibility is currently unknown. If the association 
of ERAP1 with AS relates to peptide presentation, this may 
help explain the association with HLA-B27 (Figure 3). The 
second function of ERAP1 is the cleavage of cell surface 
receptors. ERAP1 has been shown to cleave the cell surface 
receptors for the pro-inflammatory cytokines IL-1 (IL-1R2),86 
IL-6 (IL-6Rα)87 and TNF (TNFRSF1A),88 downregulating 
their signalling. Interestingly, both IL1R276 and TNFRSF1A57 
have been shown to be associated with AS. Genetic variants 
altering the receptor shedding function of ERAP1 could 
potentially have pro- or anti-inflammatory effects through 
this mechanism, however studies in mice have shown no dif-
ference in receptor shedding between Erap1-/- and C57BL/6 
control mice.57
The primary AS-associated SNP in ERAP1 is rs30187, 
which is an nsSNP encoding the protective p.Lys528Arg 
amino acid change. There is also an independent secondary 
association observed with the nsSNPs rs17482078 
(p.Arg725Gln) and rs10050860 (p.Asp575 Asn), however 
these two variants are in complete linkage disequilibrium 
(LD) and cannot be split genetically.57 The crystal structure of 
ERAP1 has recently been published,57,89 and has revealed the 
location of these altered residues around the substrate binding 
and regulatory sites of ERAP1. Peptide trimming assays 
performed using recombinant ERAP1 in vitro have shown 
that the protective rs30187 and rs17482078 variants had 
∼40% slower rates of trimming than wild-type,57 suggesting 
that they are both loss-of-function variants. It has also been 
shown that while wild-type ERAP1 is able to trim peptides to 
8- or 9-mers, the rs30187 variant stops at 11-mers.90
Gene-gene interaction between HLA-B27 and ERAP1 
has been observed, with ERAP1 association only observed 
with AS in HLA-B27 positive individuals.57 This restric-
tion in association supports the models in which abnormal 
peptide trimming or presentation by ERAP1 and HLA-B27 
contribute to HLA-B27 disease. This suggests that inhibition 
of ERAP1 may be effective in HLA-B27 positive AS.
Table 1 Confirmed candidate genes associated with AS with 
genomewide significance identified through GWAS studies1,2
Chr SNP 
rsID
Putative gene  
of interest
P value
1p31 rs11209026 IL23R 2.3 × 10-17
1q32 rs2297909 KIF21B 5.2 × 10-12
1p36 rs11249215 RUNX3 9.2 × 10-11
2q11.2 rs2310173 IL1R2 4.8 × 10-7
2p15 rs10865331 – 6.5 × 10-34
4q21 rs4389526 ANTXR2 9.4 × 10-8
5q15 rs30187 ERAP1 1.8 × 10-27
5q33 rs6556416 IL12B 1.9 × 10-8
5p13 rs10440635 PTGER4 2.6 × 10-7
6p21 rs4349859 HLA-B ,10-200
9q34 rs10781500 CARD9 1.1 × 10-6
12p13 rs11616188 TNFRSF1A 4.1 × 10-12
17q21 rs8070463 TBKBP1 5.3 × 10-8
21q22 rs378108 – 2.1 × 10-11
Abbreviation: GWAS, genome-wide association study.
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RUNX3 is a key gene involved in CD8 lymphocyte 
differentiation. This gene was identified as being associated 
with AS in the TASC/WTCCC2 GWAS,57 and this associa-
tion supports the hypothesis that HLA-B27 contributes to 
AS pathogenesis through a mechanism involving peptide 
presentation to CD8 lymphocytes. It has been shown that AS 
cases have reduced CD8 lymphocyte counts, as do healthy 
individuals who carry the AS-associated SNPs.57 These 
findings suggest that CD8 lymphocytes are involved in AS 
pathogenesis, likely in response to presentation of antigenic 
peptides by HLA-B27 after antigen processing by ERAP1.
IL-23 signalling pathway genes – IL23R, 
IL12B, STAT3
IL23R encodes the receptor for the cytokine interleukin 23 
(IL-23), which is a key regulatory cytokine essential for the dif-
ferentiation of Th17 cells (Figure 3). The association of IL23R 
suggests that Th17 cells are involved in the pathogenesis of AS 
in white European populations, as well as other IL23R associ-
ated diseases. IL23R has been found to be associated with a 
number of diseases in White European populations, including 
Crohn’s disease,91,92 psoriasis,93 and psoriatic arthritis.94 These 
diseases are all closely clinically related members of the sero-
negative group of autoimmune diseases, and this suggests that 
IL23R may partially explain their coexistence.
The association of IL23R was first reported in the 14,500 
nsSNP study75 and has been subsequently confirmed by 
two GWAS,57,76 as well as in Portuguese79 and Spanish95 
populations. Studies in Han Chinese77,78 and Koreans96 have 
shown no association with IL23R, and in these studies the 
primary associated nsSNP in white Europeans, rs11209026, 
was observed to be non-polymorphic. IL23R has also 
been shown to be not associated with Crohn’s disease in 
a Japanese population, in which rs11209026 was also not 
polymorphic.97 However, it is possible that there are rare 
AS-associated variants of IL23R in East Asian populations, 
and we have next-generation sequencing data that suggests 
that this is the case in a Han Chinese population (submitted 
for publication).
The primary AS-associated nsSNP in IL23R codes for a 
Gln381Arg substitution in exon 9, and this variant is protec-
tive against disease. There is also an independent secondary 
association with rs11209032, which lies upstream of IL23R, 
and this variant increases disease susceptibility. There have 
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Figure 3 Possible functional roles of AS-associated genes. Differentiation and function of T-cells is driven by antigen presenting cells, with IL-23 production being a key driver 
of Th17 cell function. β-glucan stimulation of the dectin-1 receptor signals through CARD9, which can drive expression of prostaglandin E2 (PGE2), which stimulates IL-23 
production through it’s receptor prostaglandin E receptor 4 (subtype EP4) (PTGER4). IL-23 signals through the IL-23 receptor (IL23R), with signal transduction proceeding 
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susceptibility is antigen presentation in the endoplasmic reticulum (ER), where ERAP1 trims antigens for peptide presentation by MHC class I molecules, such as HLA-B27. 
Altered antigen processing could alter antigen presentation, which could have an effect on RUNX3 mediated CD8 lymphocyte differentiation.
Abbreviations: APC, antigen processing cells; TCR, T-cell receptor.
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been studies in which the function of the p.Gln381 Arg 
variant have been investigated.98,99 In these studies it has been 
shown that the p.Gln381Arg variant was a loss-of-function 
change and resulted in decreased levels of IL-23 signalling. 
This resulted in lower levels of IL-23 mediated IL-17 and 
IL-22 production, as well as lower levels of circulating Th17 
and Tc17 cells. This is consistent with the increased Th17 
lymphocyte numbers65,100,101 and serum IL-17 levels102,103 
observed in AS patients. However, IL23R is also expressed 
on a number of other cell types, including γδ T cells, NK 
cells and NKT cells,104–106 and it is not clear which cell type 
is primarily affected by the disease-associated variant. Our 
data has shown there are increased levels of IL-23R+ γδ 
T cells in the peripheral blood of AS patients compared to 
healthy controls, suggesting that these cells may play a role 
in disease pathogenesis.17
The IL-12p40 subunit shared between IL-12 and IL-23 
is encoded by the gene IL12B. This gene was previously 
reported as having suggestive association with AS,7 and 
this association was later confirmed at the genome-wide 
level,57 further implicating the role of IL-23 signalling 
in AS  pathogenesis. IL12B has also been previously 
reported as being associated with both Crohn’s disease 
and  psoriasis.91,93,107
STAT3 has been shown to be associated with AS in 
both white European7 and Han Chinese78 populations, 
as well as being previously shown to be associated with 
Crohn’s disease.108 STAT3 is a critical transcription fac-
tor in the differentiation of Th17 cell populations, and is 
found directly downstream of IL-23R in the IL-23 signal-
ling cascade (Figure 3).109,110 Loss of function mutations 
in STAT3 cause Job syndrome (OMIM 147060), which 
is characterised by a loss of Th17 cells and is associated 
with recurrent, severe infections with extracellular bacteria 
and fungi.109–111
Fungal response – CARD9 and PTGER4
CARD9 and PTGER4 were both identified as being associated 
with AS in the TASC/WTCCC2 GWAS57 and have both 
previously been shown to be associated with Crohn’s disease.112,113 
CARD9 mediates signals from the innate immunity receptors 
dectin-1 and -2, which recognise β-glucan, a component of 
fungal and some bacterial cell walls. This induces the production 
of PGE
2
, which is the ligand for the prostaglandin E receptor 4, 
EP4 subtype, which is encoded by PTGER4. PTGER4 then 
induces the production of IL-23 and IL-17, promoting the 
expansion of Th17 lymphocytes (Figure 3).114 It has been 
reported that when SKG mice are treated with β-glucan they 
develop spondyloarthritis and Crohn’s disease,115 and that this 
model is characterised by activation of Th17 cells.116 This model 
suggests that involvement of the IL-23 signalling pathway in AS 
pathogenesis may be triggered by ubiquitous pathogens carrying 
β-glucan. PTGER4 has also been shown to play an anabolic role 
in bone remodelling,117,118 making it a good candidate for a role 
in the bone formation that characterises AS.
Other associated genes
IL1R2
The IL-1 gene cluster on chromosome 2q has been repeatedly 
reported as being associated with AS, with association 
observed with IL1A.119 Neither the WTCCC/TASC nsSNP 
study nor the TASC or TASC/WTCCC2 GWAS identified 
association at the IL-1 gene cluster, however the TASC 
GWAS did identify and confirm association with IL-1 
receptor, type II, IL1R2.76 Although the strongest  association 
was observed with IL1R2, the association peak is quite broad, 
and may also include association at IL1R1.
IL-1R2 binds IL-1α and IL-1β with high affinity, acting as 
a decoy receptor after cleavage from myeloid and lymphoid 
cell membranes, possibly by ERAP1.86 Further investigation 
is required to determine the disease mechanism.
ANTXR2
ANTXR2 is the gene encoding the protein capillary morpho-
genesis protein-2 (CMG2), and was identified as being asso-
ciated with AS in both the TASC76 and the TASC/WTCCC2 
GWAS.57 Recessive mutations of ANTXR2 cause juvenile 
hyaline fibromatosis (OMIM 228600) and infantile systemic 
hyalinosis (OMIM 236490), but it has not been previously 
associated with any complex diseases. It is not clear how this 
gene functionally contributes to AS pathogenesis.
2p15 and 21q22 gene deserts
The 2p15 and 21q22 intergenic regions or “gene deserts” 
have been found to be strongly associated with AS in both 
the TASC76 and TASC/WTCCC257 GWAS. There are no 
genes within 100 kb of the 2p15 peak associated region. The 
proteasome assembly chaperone 1 gene PSMG1 lies nearby 
the 21q22 locus, however it is separated by a recombination 
hotspot and it is therefore unlikely that any SNP at 21q22 
is in LD with any SNP in PSMG1. Possible mechanisms by 
which these associations contribute to disease include long-
range cis-acting regulatory regions controlling expression of 
nearby genes, or effects on non-coding RNA.
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KIF21B
The gene KIF21B encodes for a member of the family of 
kinesin motor proteins, and has been previously shown to be 
associated with Crohn’s disease. KIF21B was first identified 
as being associated with AS in a study in which genes 
previously shown to be associated with Crohn’s disease 
were investigated in an AS cohort,7 and was confirmed 
in the TASC/WTCCC2 GWAS.57 Kinesins are used for 
essential component transport along dendritic and axonal 
microtubules by neurons. The Kinesin family member 
KIF5A has been associated with rheumatoid arthritis120 and 
type-1-diabetes,121 as well as being close to a locus associated 
with multiple sclerosis.122 If the association of KIF5A is 
confirmed as true, this suggests alternate roles for kinesin 
family members.
TNFRSF1A
The association of TNFRSF1A further supports the involvement 
of TNF pathways in ankylosing spondylitis pathogenesis. In 
addition to showing association with AS, TNFRSF1A has been 
previously shown to be associated with both Crohn’s disease 
and ulcerative colitis.123,124 Additionally, a mouse model with 
constitutive over expression of TNF leads to inflammatory 
bowel disease, and sacroiliitis resembling AS, in a manner 
dependent on the expression of TNFR1,125 supporting a 
role for TNFRSF1A in AS pathogenesis. TNFRSF1A has 
also been shown to be associated with AS in a Han Chinese 
population,78 increasing the likelihood of TNFRSF1A being 
a true AS susceptibility gene.
Association has also been observed with TBKBP1, 
which encodes the TNF receptor signalling pathway mem-
ber TBK binding protein.57 Suggestive association has also 
been observed with TRADD, the TNF receptor associated 
death domain protein,57,75 and further research is needed to 
elucidate the actual disease mechanism responsible for these 
associations.
Genomic studies
Expression profiling
Although significant effort has gone into genetic studies of 
the spondylarthropies, particularly AS including the several 
large scale GWAS studies described above, large scale 
gene expression profiling studies have been somewhat less 
extensive. Other similarly prevalent inflammatory conditions 
such as RA and Lupus have been the subject of much more 
extensive study, with over 10 such studies in both diseases 
in the last two years alone.
Undertaking whole genome expression studies generates 
powerful datasets that can inform on a number of disease 
aspects;
1. Identification of genes involved in the disease pathology 
which can inform on;
a. The genes directly contributing to disease
b. Identify pathways that can be targeted therapeutically
c. Identify environmental factors that contribute to 
pathology
2. Characterise gene changes through disease progression 
to identify specific gene involvement at different disease 
stages
3. Elucidate cell- or tissue-specific genes participating in 
the disease process
4. Identify biomarkers which can be measured to:
a. Diagnose early disease
b. Catalog disease progression
c. Monitor treatment response.
Expression studies in ankylosing 
spondylitis
In most large-scale genetic studies germline DNA is used 
which can be simply extracted from blood or saliva samples. 
For the majority of these studies in relatively common 
diseases it is assumed causative mutations are germline 
making the tissue source less of a consideration. In cases of 
rarer genetically mosaic conditions such as Melorheostosis, 
issue of tissue source become extremely important. For 
expression profiling studies however sample source and han-
dling are always key considerations. The fact that expression 
profiling “snapshots” the cellular activity in the sample 
requires consideration to be given to the;
1. Disease and treatment status of the individual
2. Relevance of sample tissue site to disease presentation
3. Handling of tissue sample to minimise potential RNA 
degradation.
As described earlier there are two aspects to AS pathology, 
an initial systemic inflammation and the osteoproliferation 
and joint ankylosis characterising late disease. To monitor 
these quite different processes, careful consideration has 
to be given to the suitability of tissue sample. Systemic 
inflammation can be studied looking at the immune 
component of the blood, either through RNA extracted 
from whole blood or the peripheral blood mononuclear cell 
(PBMC) fraction which are relatively accessible. To study 
the joint disease processes is considerably more difficult. 
Biopsies of inflamed or ankylosed joints are rarely performed. 
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In cases of severe joint fusion, tissue may be obtained during 
surgery and usually only warranted in cases of very advanced 
disease where early key disease-causing changes will not 
be present.
Disease-site studies
Due to the rarity of informative axial disease-site samples 
in AS only one expression profiling study in these tissues 
has been reported. Using sacroiliac joint aspirates from SpA 
patients, Rihl et al identified sacroiliitis candidate genes 
and then validated these candidates in knee synovial fluid 
biopsies from patients with peripheral synovitis.126 They 
identified interleukin-7 (IL7) as the best candidate gene but 
the small size of the study, only 3 spondyloarthropy (SpA) 
cases and no axial tissue controls, and the small gene array 
(1200 genes) means these preliminary findings require further 
confirmation.
Despite axial inflammation being the hallmark of AS, 
significant peripheral pathology is also found in many 
patients. Knee synovial biopsies present a more accessible 
and less invasive tissue candidate for assessment of 
expression profiles at joint disease sites. To date only two 
small scale studies have been published using “macroarrays” 
(600 or 1200 genes). Both of these studies emanated from 
David Yu’s group at UCLA, one comparing osteoarthritis 
(OA) and SpA knee synovial biopsies127 and the other 
comparing SpA and RA synovial fluid mononuclear cells 
(SFMCs).128 In the SFMC study, similar patterns of inflam-
matory cytokines were expressed. One strong candidate 
gene was identified, the unfolded protein response (UPR) 
gene, immunoglobulin heavy chain binding protein (BiP). 
The UPR has been proposed as a mechanism by which 
HLA-B27 might mediate its role in AS.129 In the synovial 
biopsy study, SpA and OA samples could be differentiated 
by their expression profiles, however candidates were not 
validated.
Our group has recently undertaken an expression 
profiling study in SpA synovial biopsies using a different 
approach. Rather than using fresh-frozen biopsies we have 
utilised Illumina’s Whole-Genome DASL® (cDNA- mediated 
Annealing, Selection, Extension, and Ligation [Illumina Inc, 
San Diego, CA]) Gene Expression Assay which has been 
specifically developed for whole-genome expression profiling 
of degraded RNA samples from archived tissue biopsies. We 
analyzed the expression profile of 24000 cDNAs in synovial 
biopsy samples from seronegative spondyloarthropy, AS and 
osteoarthritis patients and normal control samples (submitted 
for  publication). Several interesting candidate genes were 
identified. Matrix metalloproteinase 3 (MMP3), a gene 
associated with inflammation and bone and cartilage remod-
elling was strongly upregulated and immunohistochemical 
confirmation showed MMP3 expression was particularly 
high in AS biopsies. MMP3 has previously been identified 
as a circulating biomarker of AS.23,130,131 Dickkopf-3 (DKK3), 
a Wnt pathway inhibitor, was downregulated. With the Wnt 
pathway having being recently hypothesised as playing a 
key role in AS-associated osteoproliferation132–134 this was 
particularly interesting. Gene ontology analysis also showed 
altered immune and inflammation pathways and more 
interestingly changes in extracellular matrix and osteoblast 
associated pathways.
Use of peripheral joint samples for expression profiling 
in AS is not ideal and interpretation of these findings must be 
undertaken carefully. Unfortunately however axial samples 
are extremely rare. They are certainly valuable in identifying 
unique profiles for AS in relation to RA and/or OA samples to 
eliminate general inflammatory/joint damage genes. Further, 
many of the early changes in inflammation-mediated cell 
activity initiating tissue damage would be similar in both 
peripheral and axial joints.
With the limited number of disease-site studies having 
been undertaken in AS/SpA, little consensus on key genes 
have been found. Even using peripheral joint samples, experi-
mental cohorts are small and usually lack sufficient numbers 
to allow independent validation. To generate sufficient power, 
consortium approaches should be considered and utilisation 
of technologies such as DASL to probe archived samples 
would further increase the numbers of samples available 
to profile.
Circulating cell studies
As described above, there is also a systemic immune-
mediated inflammatory component in AS in addition to the 
osteoproliferation seen in the axial joints. Thus peripheral 
blood presents an inviting target tissue to try and elucidate the 
underlying gene changes that contribute to the early aspects 
of AS/SpA. The comparative ease with which samples of 
peripheral blood can be obtained has also meant that expres-
sion profiling studies using this RNA source in AS/SpA (as 
well as many other immune-mediated diseases) have been 
better powered and more numerous than those described 
above in joint tissue.
In AS the circulating immune cells may reflect the early 
changes that contribute both to disease susceptibility and also 
early stage progression. Most studies to date have utilised 
the peripheral blood mononuclear cell (PBMC) fraction from 
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whole blood which contains the circulating white blood cells 
including B, T and NK cells, monocytes and granulocytes. 
Although a widely utilised standard protocol, purification 
of PBMCs does take several hours and needs to be carried 
out within 48 hours of blood collection, preferably within a 
few hours. This is particularly true for transcriptomics where 
differences in cell handling could cause significant shifts in 
gene expression patterns. PBMCs can therefore by unsuit-
able for studies involving multiple centers or tissue sampling 
from more remote or distant  locations. An alternative blood-
derived RNA source is to use whole blood. Two kits have been 
specifically developed for transcriptomic studies in whole 
blood with the blood collected into an RNA preservative 
which stabilises the RNA allowing shipping/initial storage at 
room temperature with minimal degradation (PAXgene from 
Qiagen [Valencia, CA] or Tempus from Invitrogen/Applied 
Biosystems [Life Technologies, Grand Island, NY]).
Three whole genome expression profiling studies have 
been published using whole blood in spondylarthropy all 
using the PAXgene technology.135–137 Sharma et al compared 
healthy controls and spondyloarthropy patients but used a 
slightly unusual approach. Rather than analysing a main 
sample group by microarray then confirming candidate genes 
by qPCR in a second cohort, they split the sample groups into 
a discovery and a validation set and microarrayed both groups 
and compared differentially expressed genesets.137 However, 
the control and patient groups had significant imbalances 
in their gender mix, as well as no joint disease scores being 
ascertained making interpretation difficult. Both Assassi et al 
and Pimental-Santos et al focussed on AS, using patients with 
confirmed AS according to the Modified New York Criteria, 
with Assassi also comparing their datasets with those from 
systemic lupus erythematosus (SLE) and systemic sclerosis 
(SSc) patients.135,136 Both these studies undertook an initial 
microarray study and confirmed candidate genes by qPCR in 
a larger 2nd cohort. The Pimentel-Santos study was the largest 
study with 18 patients and 18 controls in the initial microarray 
cohort and validated in 156 patients and controls using Taqman 
Low Density Arrays (TLDAs). Interestingly all three studies 
identified elements of the innate immune system to be differen-
tially regulated. TLRs 4 and 5,135,136 NLRP2137 and CLEC4D136 
were all shown to be differentially expressed. Interestingly 
TLR4 was also shown to be up regulated at both RNA and 
protein level in AS PBMCs in a candidate gene study138 as well 
as in degenerative intervertebral discs.139 A role for the innate 
system in AS has long been postulated due to the proposed 
link between an as yet unknown pathogen and disease onset.140 
SPARC, a bone matrix protein, was also upregulated in two 
of the studies136,137 which suggests dysregulation of the bone 
matrix which might contribute to the joint ankylosis.
In other immune conditions many studies have been 
undertaken using PBMCs however this is not the case for 
SpA/AS. The first SpA expression profiling study used a 
small (588-gene) array comparing a small control, SpA, 
RA, and psoriatic arthritis patient cohort (n = 6–7).141 An 
arthritis-specific gene signature was identified but only one 
gene, myeloid cell nuclear differentiation antigen (MNDA), 
was able to distinguish SpA from the other arthrites.
Colbert and colleagues adopted a different approach 
undertaking a large whole genome study (∼40000 cDNAs) 
using purified macrophages derived from normal and AS 
PBMC samples.142 They demonstrated a ‘reversed’ IFNγ 
signature, with reduced expression of both IFNγ and IFNγ-
induced genes.
Gene expression profiling is also a powerful tool to 
 follow response to treatment. Haroon et al used whole 
genome expression arrays to identify a response to anti-
TNF  treatment.143 A subset of 1428 genes was differentially 
expressed in response to treatment and downregulation of 
4 inflammation-associated genes, including LIGHT, whose 
downregulation has also been associated with RA suggest-
ing this gene maybe generally associated with inflammatory 
processes,144 was confirmed.
Only recently however have large-scale whole genome 
expression profiling studies on the complete PBMC popu-
lation been undertaken in AS or SpA by ourselves145 and 
David Yu’s group at UCLA.146 Using Illumina’s HT-12 whole 
genome arrays we compared expression profiles of PBMCs 
from 18 active AS patients (confirmed by Modified New York 
Criteria) and 18 age- and gender-matched controls identifying 
a 452-gene signature delineating AS and control samples 
with 94% accuracy. Downregulation of four immune/ 
inflammation candidate genes, NR4A2, TNFAIP3, CD69, 
and RORA, was validated by qPCR. The expression pattern 
of these four genes generated a diagnostic potential of ∼80% 
for AS which has the potential to be used to distinguish 
inflammatory from non-inflammatory back pain.
The downregulation of these candidate genes, together 
with other immune genes, suggests a defect in the capacity 
of the immune response. In most inflammatory condi-
tions an upregulation of inflammation-associated genes 
would be expected, such as in RA and systemic lupus 
erythematosus.147–151 Our results however are consistent with 
the macrophage study described above which also detailed a 
decreased immune response.142 They also saw a decrease in 
TNFAIP3 expression in AS patients.
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Down-regulation or muting of the immune response 
is compatible with one of the hypotheses proposed for the 
underlying pathology causing AS, in which a ubiquitous 
environmental factor acts as a trigger in patients genetically 
disposed to the disease (such as carrying the HLA-B27 allele 
together with other susceptibility alleles from other genes 
such as IL23R and ERAP1).152 A microarray study on whole 
blood samples from psoriatic arthritis patients, a related 
spondyloarthropy, also showed a general down-regulation in 
immune-associated genes suggesting inappropriate immune 
control.153
In addition to comparing AS and control groups, 
Gu et al also looked at undifferentiated SpA (uSpA) 
patients.146 Expression changes were significantly greater 
in the uSpA patients compared to controls than for the 
AS samples. Given that uSpA is considered a less severe 
disease this was somewhat unexpected. Very few genes 
altered in AS with most of those being up-regulated 
including NR4A2 which was downregulated in our study.145 
The Gu et al study was undertaken in a Chinese patient 
cohort which might explain the different findings to our 
Caucasian cohort study.
Table 2 summarises the most interesting genes identified 
through whole genome expression profiling studies in well-
powered studies.
As mentioned above, expression profiling can gener-
ate powerful diagnostic algorithms. In AS, advanced joint 
damage is required for firm diagnosis (Modified New York 
Criteria) to gain subsidized access to the most effective (and 
expensive) treatments. A need for a reliable early diagnostic 
in AS is thus very pressing. Both ours145 and David Yu’s146 
studies showed diagnostic power . 80% to predict disease 
based on the expression profiles.
The results to date have shown a disappointing lack of 
overlap between the whole blood and PBMC expression 
studies. Several studies have reported differences in the 
expression profile of PBMCs vs whole blood.154–157 Larger 
cohort studies are required with whole blood profiling the 
more convenient vehicle to expedite the multicenter approach 
needed to generate sufficient power.
To date a number of disparate expression profiling studies 
have been undertaken in AS. Although a number of poten-
tially interesting gene changes have been identified, there 
is a lack of consensus in the mechanisms highlighted save 
for an indication of a reduced immune response. A similar 
problem confronted genetic studies several years ago and this 
was overcome by large-scale collaborative studies generating 
large homogenous sample cohorts and enabled strong repro-
ducible candidate gene-associations to be identified. Similar 
issues need to be addressed for future expression profiling 
studies in AS. Significant thought must be given to assem-
bling large informative sample cohorts that reflect the stage 
of disease being investigated. These cohorts need to consist 
of homogenous case collections targeting specific disease 
Table 2 Candidate genes associated with AS identified through genome-wide expression studies
Gene Samples Tissue Platform Regulation References
MMP3 AS-SpA vs normal-OA Synovial biopsy illumina DASL Up Submitted for 
publication
DKK3 AS-SpA vs normal-OA Synovial biopsy illumina DASL Down Submitted for 
publication
TLR4 AS vs controls Whole blood (PAXGene) illumina HT12 Up 135,136
TLR5 AS vs controls Whole blood (PAXGene) illumina HT12 Up 135,136
NLRP2 SpA vs controls Whole blood (PAXGene) Affymetrix HG-U133 plus 2.0 Down 137
CLEC4D AS vs controls Whole blood (PAXGene) illumina HT12 Up 136
SPARC SpA vs controls AS vs  
controls
Whole blood (PAXGene) Affymetrix HG-U133 plus 2.0 
illumina HT12
Up 136,137
IFN-regulated genes AS vs controls Purified macrophages Affymetrix HG-U133 plus 2.0 Reverse  
iFN signature
142
LIGHT AS patients with and without  
anti-TNF treatment
whole blood Affymetrix HG-U133 plus 2.0 Down 143
NR4A2 AS vs controls PBMC illumina HT12 Down 145
TNFAIP3 AS vs controls PBMC 
Purified macrophages
illumina HT12 
Affymetrix HG-U133 plus 2.0
Down 142,145
CD69 AS vs controls PBMC illumina HT12 Down 145
RORA AS vs controls PBMC illumina HT12 Down 145
NR4A2 AS vs uSpA vs controls PBMC Illumina Ref-8 Up 146
RGS1 AS vs uSpA vs controls PBMC Illumina Ref-8 Up 146
Abbreviations: PBMC, peripheral blood mononuclear cells; AS, ankylosing spondylitis; SpA, spondyloarthropathy; USpA, undifferentiated spondyloarthropathy; 
OA, osteoarthritis; iFN, interferon.
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stages, such as early inflammation or late-stage ankylosis, to 
stand the best chance of being informative. For the develop-
ment of diagnostic tests, further studies need to be conducted 
on the suitability of whole blood RNA as a sample source 
reflective of disease status, as this approach is much more 
practical for use in clinical practice. Given the scarcity of 
clinically relevant samples, collaborative approaches would 
enable such powerful studies. Archived samples should also 
be utilized using the appropriate technologies developed for 
such approaches.
With next generation sequencing enabling whole tran-
scriptome studies the future of expression profiling looks 
to lie in this direction. Costs are rapidly decreasing making 
large scale studies viable for well-funded labs. RNAseq will 
allow the full catalog of splice variants, non-coding RNAs 
and microRNAs to be elucidated and some of these novel 
species may explain some of the strong GWAS hits in “gene 
deserts”.
Conclusion
Although a number of strong candidate genes have been 
identified from well-powered GWAS studies there appears 
to be little correlation with the gene expression profiling 
studies published to date.
This could be due to;
1. Genetic studies identify for the most part susceptibility 
genes and expression studies are frequently in patients 
with established disease. Many alterations in these genes 
may be finished by the time the expression studies are 
undertaken
2. Genetic studies may identify genes in which function 
rather than absolute expression level is altered
3. Genetic disposition to a disease may be the result of very 
small changes in a number of genes, each of which is 
below the threshold of detection by expression profiling 
but cumulatively might generate significant downstream 
effects which are picked up by the expression studies.
To date no expression quantitative trait loci (eQTL) 
 studies have been published in AS or SpA. There is now 
a significant body of GWAS and expression profiling 
data to enable such studies. Such approaches correlating 
genetic variants with both cis- and trans expression may 
further explain to current GWAS/expression profiling dis-
connect and further reveal the pathways and mechanisms 
underlying AS.
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